A Randomized Comparison of Chloroquine Versus Dihydroartemisinin–Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam
Authors:
- Phung Duc ThuanPTPhung Duc Thuan
- Nguyen Thuy Nha CaNCNguyen Thuy Nha Ca
- Pham Van ToiPTPham Van Toi
- Nguyen Thanh Thuy NhienNNNguyen Thanh Thuy Nhien
- Ngo Viet ThanhNTNgo Viet Thanh
- Nguyen Duc AnhNANguyen Duc Anh
- Nguyen Hoan PhuNPNguyen Hoan Phu
- Cao Quang ThaiCTCao Quang Thai
- Le Hong ThaiLTLe Hong Thai
- Nhu Thi HoaNHNhu Thi Hoa
- Le Thanh DongLDLe Thanh Dong
- Mai Anh LoiMLMai Anh Loi
Open Access
- 6 April 2016
- journal article
- research article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 94 (4) , 879-885
Abstract
A total of 128 Vietnamese patients with symptomatic Plasmodium vivax mono-infections were enrolled in a prospective, open-label, randomized trial to receive either chloroquine or dihydroartemisinin–piperaquine (DHA-PPQ). The proportions of patients with adequate clinical and parasitological responses were 47% in the chloroquine arm (31 of 65 patients) and 66% in the DHA-PPQ arm (42 of 63 patients) in the Kaplan–Meier intention-to-treat analysis (absolute difference 19%, 95% confidence interval = 0–37%), thus establishing non-inferiority of DHA-PPQ. Fever clearance time (median 24 versus 12 hours, P = 0.02), parasite clearance time (median 36 versus 18 hours, P < 0.001), and parasite clearance half-life (mean 3.98 versus 1.80 hours, P < 0.001) were all significantly shorter in the DHA-PPQ arm. All cases of recurrent parasitemia in the chloroquine arm occurred from day 33 onward, with corresponding whole blood chloroquine concentration lower than 100 ng/mL in all patients. Chloroquine thus remains efficacious for the treatment of P. vivax malaria in southern Vietnam, but DHA-PPQ provides more rapid symptomatic and parasitological recovery.Keywords
This publication has 19 references indexed in Scilit:
- Plasmodium vivax treatmentsCurrent Opinion in Infectious Diseases, 2011
- Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimatorMalaria Journal, 2011
- Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled TrialClinical Infectious Diseases, 2011
- The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009PLOS Neglected Tropical Diseases, 2010
- Artemisinin combination therapy for vivax malariaThe Lancet Infectious Diseases, 2010
- Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trialMalaria Journal, 2010
- Artemisinin Resistance inPlasmodium falciparumMalariaNew England Journal of Medicine, 2009
- Glucose-6-phosphate dehydrogenase (G6PD) mutations and haemoglobinuria syndrome in the Vietnamese populationMalaria Journal, 2009
- Resistance to Therapies for Infection byPlasmodium vivaxClinical Microbiology Reviews, 2009
- Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparisonThe Lancet, 2007